Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice.

[1]  H. Randeva,et al.  Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice , 2019, Molecular and Cellular Endocrinology.

[2]  R. Eckel,et al.  Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[3]  H. Randeva,et al.  Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice , 2018, Cardiovascular Diabetology.

[4]  N. Chattipakorn,et al.  Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors , 2018, Cardiovascular Diabetology.

[5]  B. Zinman,et al.  Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial , 2018, Diabetologia.

[6]  A. Murphy,et al.  SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr-/- type 1 diabetic mice. , 2018, Atherosclerosis.

[7]  B. Zinman,et al.  Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease. , 2018, Journal of the American College of Cardiology.

[8]  L. Ghiadoni,et al.  Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study , 2017, Cardiovascular Diabetology.

[9]  K. Hirata,et al.  Novel mechanism of regulation of the 5-lipoxygenase/leukotriene B4 pathway by high-density lipoprotein in macrophages , 2017, Scientific Reports.

[10]  T. Guzik,et al.  Perivascular adipose tissue inflammation in vascular disease , 2017, British journal of pharmacology.

[11]  J. Yudkin,et al.  Exercise effects on perivascular adipose tissue: endocrine and paracrine determinants of vascular function , 2017, British journal of pharmacology.

[12]  T. Asano,et al.  The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice , 2017, International journal of molecular sciences.

[13]  K. Lackner,et al.  The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats , 2017, Redox biology.

[14]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[15]  Y. Higashikuni,et al.  Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice. , 2017, Vascular pharmacology.

[16]  A. Nishiyama,et al.  Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure , 2017, Hypertension Research.

[17]  K. Park,et al.  The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE−/− mice fed a western diet , 2017, Diabetologia.

[18]  X. Ouyang,et al.  The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE−/− Mice , 2016, Mediators of inflammation.

[19]  Changwei Liu,et al.  Perivascular adipose tissue alleviates inflammatory factors and stenosis in diabetic blood vessels. , 2016, Biochemical and biophysical research communications.

[20]  M. Sata,et al.  Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse , 2016, Front. Cardiovasc. Med..

[21]  M. Pfeffer,et al.  Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. , 2016, The New England journal of medicine.

[22]  J. L. Edwards.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[23]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[24]  T. Hirano,et al.  Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice , 2015, PloS one.

[25]  Y. Higashikuni,et al.  Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. , 2015, Atherosclerosis.

[26]  S. Yamagishi,et al.  Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis , 2015, Hormone and Metabolic Research.

[27]  T. Münzel,et al.  The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity , 2014, PloS one.

[28]  H. Koepsell,et al.  Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. , 2014, American journal of physiology. Renal physiology.

[29]  C. Kim,et al.  Resistin derived from diabetic perivascular adipose tissue up-regulates vascular expression of osteopontin via the AP-1 signalling pathway , 2013, The Journal of pathology.

[30]  R. Webb,et al.  Perivascular adipose tissue: more than just structural support. , 2012, Clinical science.

[31]  P. Vanhoutte,et al.  Endothelium‐mediated control of vascular tone: COX‐1 and COX‐2 products , 2011, British journal of pharmacology.

[32]  Tetsuya Kitagawa,et al.  Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. , 2011, Journal of the American College of Cardiology.

[33]  C. Sobey,et al.  Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets , 2011, Nature Reviews Drug Discovery.

[34]  R. M. Lee,et al.  Alterations in perivascular adipose tissue structure and function in hypertension. , 2011, European journal of pharmacology.

[35]  S. Narumiya,et al.  Roles of prostanoids in the pathogenesis of cardiovascular diseases: Novel insights from knockout mouse studies. , 2011, Pharmacology & therapeutics.

[36]  M. Isobe,et al.  Roles of prostaglandin E2 in cardiovascular diseases. , 2011, International heart journal.

[37]  J. Badimón,et al.  Prostanoid and TP-receptors in atherothrombosis: Is there a role for their antagonism? , 2010, Thrombosis and Haemostasis.

[38]  M. Alloosh,et al.  Epicardial Perivascular Adipose-Derived Leptin Exacerbates Coronary Endothelial Dysfunction in Metabolic Syndrome via a Protein Kinase C-&bgr; Pathway , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[39]  R. Henry,et al.  SGLT2 inhibition — a novel strategy for diabetes treatment , 2010, Nature Reviews Drug Discovery.

[40]  N. Weintraub,et al.  Crosstalk between perivascular adipose tissue and blood vessels. , 2010, Current opinion in pharmacology.

[41]  B. Jeppsson,et al.  p38 Mitogen‐activated protein kinase signalling regulates vascular inflammation and epithelial barrier dysfunction in an experimental model of radiation‐induced colitis , 2010, The British journal of surgery.

[42]  E. Dickson,et al.  Proinflammatory Phenotype of Perivascular Adipocytes: Influence of High-Fat Feeding , 2009, Circulation research.

[43]  R. M. Lee,et al.  Effects of fetal and neonatal exposure to nicotine on blood pressure and perivascular adipose tissue function in adult life. , 2008, European journal of pharmacology.

[44]  J. Stallone,et al.  Sympathy for the devil: the role of thromboxane in the regulation of vascular tone and blood pressure. , 2008, American journal of physiology. Heart and circulatory physiology.

[45]  O. Pedersen,et al.  Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.

[46]  R. M. Lee,et al.  Modulation of vascular function by perivascular adipose tissue: the role of endothelium and hydrogen peroxide , 2007, British journal of pharmacology.

[47]  N. Agrawal,et al.  Atherosclerosis in diabetes mellitus: role of inflammation. , 2007, Indian journal of medical sciences.

[48]  A. Koller,et al.  Up-regulation of vascular cyclooxygenase-2 in diabetes mellitus. , 2006, Pharmacological reports : PR.

[49]  K. Schrör.  Prostaglandins, other eicosanoids and endothelial cells , 1985, Basic Research in Cardiology.

[50]  T. Imaizumi,et al.  Advanced glycation end products (AGEs) and diabetic vascular complications. , 2005, Current diabetes reviews.

[51]  P. Ganz,et al.  Role of Endothelial Dysfunction in Atherosclerosis , 2004, Circulation.

[52]  A. Manning,et al.  Targeting JNK for therapeutic benefit: from junk to gold? , 2003, Nature Reviews Drug Discovery.

[53]  P. Libby,et al.  Diabetic macrovascular disease: the glucose paradox? , 2002, Circulation.

[54]  A. Rigotti,et al.  Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B type I-deficient mice. , 2001, Journal of lipid research.

[55]  K. Kugiyama,et al.  Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. , 1999, Journal of the American College of Cardiology.